




# Utilizing ACIP's Updated Pneumococcal Recommendations

## RAPID RECAP

**Low vaccination rates for patients  $\geq 65$  years of age and ages 18-64 with increased risk contribute to a high burden of pneumococcal disease.<sup>1,2</sup>**

**Estimated burden of pneumococcal disease in U.S. adults aged  $\geq 19$  years:**

- In 2017,  $\geq 100,000$  hospitalized pneumococcal pneumonia cases occurred<sup>1</sup>
- In 2019,  $\sim 30,000$  IPD cases and  $\sim 3,000$  IPD deaths occurred<sup>2</sup>
  - $\sim 43\%$  of IPD in adults aged  $\geq 65$  years
  - $\sim 48\%$  of IPD in adults aged 19–64 years with risk-based indications
- 90% of the current adult IPD burden is in persons aged 19–64 years with risk-based indications and persons aged  $\geq 65$  years





# Utilizing ACIP's Updated Pneumococcal Recommendations

## RAPID RECAP

In February of 2022, the Advisory Committee on Immunization Practices published updated recommendations for pneumococcal immunizations based on age and factors that increase risk of pneumonia.<sup>4</sup>

### Ages 18-64 With Increased Risk

Factors that Increase Risk	Previous Recommendations	Current Recommendations*
<b>Chronic Medical Conditions</b>	PPSV23	PCV15 and PSV23 or PCV20
<b>Cochlear Implant, CSF Leak</b>	PCV13 then PPSV23	
<b>Immunocompromising Conditions</b>	PCV13 then PPSV23 repeat PPSV23 after 5 years	

### Ages ≥65 years

Factors that Increase Risk	Previous Recommendations	Current Recommendations*
<b>With Chronic Medical Conditions</b>	PCV13 (if not given earlier) followed by PPSV23 (final dose at age 65 or older)	PCV15 and PSV23 or PCV20
<b>Age-Related Only</b>	PPSV23, can give PCV13 first if clinical shared decision making indicates	

\*As of February 2022



# Utilizing ACIP's Updated Pneumococcal Recommendations

## RAPID RECAP

Updated CDC recommendations based on current pneumococcal immunization status can be summarized as follows:<sup>5</sup>

### Not previously vaccinated/unknown

Give PCV15 followed by PPSV23 a year later  
– OR –  
Give PCV20

### Previously received PPSV23

Give one dose of PCV15 or PCV20 at least  
1 year after PPSV23 dose

### Previously received PCV13 and PPSV23 at age less than 65

Give PPSV23 per previous recommendations  
1 dose of PCV20 can be given if PPSV23 not  
available

### Previously received PCV13 at any age

Give PPSV23 per previous recommendations  
1 dose of PCV20 can be given if PPSV23 not  
available

The SHARE model provides a structured approach to immunization discussions with patients.<sup>6</sup>

**S**

**SHARE tailored reasons** why the vaccine is right for the patient given his or her age, health status, lifestyle, occupation, or other risk factors

**H**

**HIGHLIGHT positive experiences** with vaccines (personal or in your practice), as appropriate, to reinforce the benefits and strengthen confidence in influenza vaccination

**A**

**ADDRESS patient questions** and any concerns about the vaccine, including side effects, safety, and vaccine effectiveness in plain and understandable language

**R**

**REMIND patients that vaccines protect them and their loved ones** from serious illnesses and complications

**E**

**EXPLAIN the potential costs of getting infectious diseases**, including serious health effects, time lost (such as missing work or family obligations), and financial costs



# Utilizing ACIP's Updated Pneumococcal Recommendations

## RAPID RECAP

### Resources

1. CDC SNIIPP, 2017. <https://www.cdc.gov/pneumococcal/surveillance.html>
2. CDC ABCs, 2018. <https://www.cdc.gov/abcs/overview/index.html>
3. <https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/vaccination-coverage-adults-2019-2020.html>
4. [https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm?s\\_cid=mm7104a1\\_w](https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm?s_cid=mm7104a1_w)
5. <https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf>
6. <https://www.nfid.org/2015/08/18/a-strong-vaccine-recommendation-makes-a-difference/>